Riga virus is the first virotherapy medication in the world, which has been approved for clinical use, and in 2004 it was registered in Latvia for treatment of malignant melanoma. In 2015 medication was approved in Georgia and in 2016 – in Armenia. It is the only clinically approved non-genetically modified oncolytic virus in the world. Virotherapy with Riga virus prolongs recurrence-free survival period, prolongs patients' survival and improves life quality.
Currently this medication is fully subsidised by the state for Latvian patients suffering from malignant melanoma and it is included in clinical guidelines approved by the National Health Service of Latvia. In 2016 medicinal product manufacturer received a grant from the European Commission programme "Horizon 2020", sub-programme "Aid for biotechnologies to promote new product sales in European market" aiming at registering the medicinal product in the European Union market (EMEA).
This medicinal product is intramuscularly injected into a body pursuant to tailor-made treatment protocols. Usually treatment takes place on out-patients basis with mild side effects. The most common side effect is slightly increased body temperature lasting from one to three days.
For more information visit our homepage www.rigvir.com
← Go back